Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lybalvi long-term safety extension in schizophrenia and bipolar I disorder
NCT03201757Phase 3Completed
- Sponsor
- Alkermes
- Start
- Jun 2017
- Primary completion
- Sep 2023
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 13
01
Overview
A Phase 3 trial of olanzapine + samidorphan in schizophrenia, schizophreniform disorder, bipolar I disorder, sponsored by Alkermes. Started Jun 2017; status: completed.
02
Drugs
olanzapine + samidorphan
03
Conditions
schizophreniaschizophreniform disorderbipolar I disorder
Beyond the preview
Go deeper on NCT03201757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03201757.